Phaseline

Targets › XDH

XDH (Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase): drug programs, companies and trials

14 programs from 12 companies in 16 trials: 6 Phase 2, 4 Phase 3, 3 Phase 1, 3 Phase 4; Metabolic and endocrine, Cardiovascular, Gastroenterology; next expected readout Nov 2026.

Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. (UniProt, P47989)

Open in Phaseline: the race on XDH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bangladesh Medical UniversityAllopurinol
Xanthine dehydrogenase inhibitor
XDHPhase 4Cirrhoses, LiverDec 2026
Seoul National University HospitalFebuxostat
Xanthine dehydrogenase inhibitor
XDHPhase 4GoutFeb 2027
Massachusetts General HospitalAllopurinol
Xanthine dehydrogenase inhibitor
XDHPhase 4GoutSep 2028
Arthrosi TherapeuticsXOI High Dose
Xanthine oxidase inhibitor
XDHPhase 3GoutNov 2026
Innovent Biologics Technology Limited (Shanghai R&D Center)Tigulixostat (IBI128)
Xanthine dehydrogenase inhibitor
XDHPhase 3GoutApr 2027
Poznan University of Medical SciencesAllopurinol
Xanthine dehydrogenase inhibitor
XDHPhase 3Cardiovascular DiseasesJul 2028
dr. M.J.N.L. BendersAllopurinol
Xanthine dehydrogenase inhibitor
XDHPhase 3Congenital Heart Disease in ChildrenDec 2028
Arthrosi TherapeuticsXOI Low Dose
Xanthine oxidase inhibitor
XDHPhase 2GoutNov 2026
Tanta UniversityFebuxostat
Xanthine dehydrogenase inhibitor
XDHPhase 2Non Alcoholic Steatohepatitis; Intracranial HemorrhageDec 2026
Tanta UniversityAllopurinol
Xanthine dehydrogenase inhibitor
XDHPhase 2DepressionMay 2027
Maastricht University Medical CenterFebuxostat
Xanthine dehydrogenase inhibitor
XDHPhase 2Non-Small Cell Lung CancerJun 2027
Shenyang Sunshine PharmaceuticalSSS11 (Pegylated Recombinant Candida Utilis Uricase)
Urate oxidase - converts uric acid to allantoin
XDHPhase 1GoutDec 2026
Shanghai Institute Of Biological ProductsSIBP-R002 (Peguricase for injection)
Non-selective xanthine oxidase inhibitor
XDHPhase 1GoutDec 2026
Fujita Health UniversityFebuxostat
Xanthine dehydrogenase inhibitor
XDHPhase 1Parkinson's Disease (PD)–

Conditions

Gout (8) Non Alcoholic Steatohepatitis (1) Intracranial Hemorrhage (1) Non-Small Cell Lung Cancer (1) Parkinson's Disease (PD) (1) Depression (1) Cirrhoses, Liver (1) Congenital Heart Disease in Children (1) Cardiovascular Diseases (1)

Modalities

small molecule (11), mixed (2), protein or peptide (1)

Companies

Tanta University (2) Arthrosi Therapeutics (2) Maastricht University Medical Center (1) Fujita Health University (1) Seoul National University Hospital (1) Bangladesh Medical University (1) dr. M.J.N.L. Benders (1) Poznan University of Medical Sciences (1) Massachusetts General Hospital (1) Shenyang Sunshine Pharmaceutical (1) Shanghai Institute Of Biological Products (1) Innovent Biologics Technology Limited (Shanghai R&D Center) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.